Can the U.S. turmoil make this Europe’s moment to shine? A Perspective

In the 18 years I’ve been covering the biopharma industry, FDA and NIH have always been the unquestioned gold standard for regulating the sector and fueling the basic research necessary to advance new, innovative therapeutics. But for the next three and-a-half years — maybe even longer — there’s a real risk of these U.S. institutions no longer filling those roles. For Europe, that risk could also be an opportunity.

The changes underway at FDA and NIH do not have to spell doom for the industry. Over the course of these 18 years, I’ve also witnessed the biopharma sector bloom into a global one, with expertise and competencies spread well beyond the U.S. ...